Form SC 13G - Statement of acquisition of beneficial ownership by individuals
August 28 2023 - 4:57PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. )*
Eterna
Therapeutics Inc.
(Name
of Issuer)
Common
stock, par value $0.005 per share
(Title
of Class of Securities)
114082209
(CUSIP
Number)
April
3, 2023
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
| * | The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page. |
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
1 |
|
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Purchase Capital LLC |
2 |
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
3 |
|
SEC Use Only
|
4 |
|
Citizenship or Place of Organization.
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With |
|
5 |
|
Sole Voting Power
121,822(1) |
|
6 |
|
Shared Voting Power
0 |
|
7 |
|
Sole Dispositive Power
280,422(1) |
|
8 |
|
Shared Dispositive Power
0 |
9 |
|
Aggregate Amount Beneficially Owned by Each Reporting Person
280,422(1) |
10 |
|
Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)
☐ |
11 |
|
Percent of Class Represented by Amount in Row (9)*
5.0%(2) |
12 |
|
Type of Reporting Person (See Instructions)
OO |
| (1) | Consists of (i) 121,822
shares of common stock, par value $0.005 per share (the “Common Stock”), of Eterna Therapeutics Inc., a Delaware
corporation (the “Issuer”) held by Purchase Capital LLC (“Purchase Capital” or the
“Reporting Person”) and (ii) 158,600 shares of Common Stock issuable upon the exercise or conversion, as
applicable, of the Purchase Capital Derivative Securities (as defined below). Purchase Capital acquired 141,644 warrants (the
“December 2022 Warrants”) from the Issuer in a private placement (the “December 2022 Private
Placement”), each of which became exercisable on June 2, 2023 to purchase one share of Common Stock, with an exercise
price of $3.28 per share. On July 14, 2023, Purchase Capital acquired from the Issuer in a private placement (the
“July 2023 Private Placement”): (i) $1,000,000 in principal amount of the Issuer’s 6.0% Senior
Convertible Promissory Notes due July 2028 (the “Note”) and (ii) 699,300 warrants, each exercisable to purchase
one share of the Common Stock, at an exercise price of $2.61 per share (the “July 2023 Warrants, together with the Note
and the December 2022 Warrants, the “Purchase Capital Derivative Securities”). The Notes may be converted into
shares of Common Stock at a conversion price of $2.86 per share, subject to customary adjustments for stock splits, stock dividends
and recapitalizations, as described in the Notes. Purchase Capital may not exercise or convert, as applicable, the Purchase Capital
Derivative Securities to the extent that the aggregate number of shares of Common Stock beneficially owned by Purchase Capital or
any other person with whom shares of Common Stock would be aggregated for purposes of determining beneficial ownership under Section
13 of the Securities Exchange Act of 1934, as amended, including Nicholas J. Singer, its affiliate, would exceed 9.99% immediately
after exercise thereof; therefore, Purchase Capital beneficially owns only 158,600 shares underlying the Purchase Capital Derivative
Securities, the balance of which Purchase Capital does not have the right to acquire. Mr. Singer filed Amendment No. 1 to Schedule
13D on July 26, 2023 disclosing his beneficial ownership of 9.99% of the Common Stock. |
| (2) | Calculated
based on an aggregate of 5,410,331 shares of Common Stock outstanding as of July 14, 2023 as set forth in that certain Securities Purchase
Agreement filed as an exhibit to the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July
18, 2023. |
Item 1.
Eterna
Therapeutics Inc.
(b) |
Address
of Issuer’s Principal Executive Offices |
1035
Cambridge Street, Suite 18A
Cambridge,
MA 02141
Item 2.
This
statement is filed by Purchase Capital LLC, a Delaware limited liability company (“Purchase Capital” or the “Reporting
Person”).
| (b) | Address
of Principal Business Office or, if none, Residence |
The
address of the principal business office for Purchase Capital is:
1395
Brickell Avenue, Suite 800
Miami,
Florida 33131
See
Row 4 of the Reporting Person’s cover page.
| (d) | Title
of Class of Securities |
Common
stock, par value $0.005 per share.
114082209
Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not
applicable.
Item 4.
Ownership
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
The
information contained in Item 5 through and including Item 11 on the Reporting Person’s cover page of this Schedule 13G, including
the footnotes thereto, is incorporated by reference in this Item 4.
Item 5.
Ownership of Five Percent or Less of a Class
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following ☐.
Item 6.
Ownership of More than Five Percent on Behalf of another Person
Not
applicable.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not
applicable.
Item 8.
Identification and Classification of Members of the Group
Not
applicable.
Item 9.
Notice of Dissolution of Group
Not
Applicable.
Item 10.
Certification
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
August
28, 2023
PURCHASE CAPITAL LLC |
|
|
|
|
By: |
/s/
Nicholas J. Singer |
|
Name: |
Nicholas J. Singer |
|
Title: |
Managing Partner |
|
5
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Apr 2024 to May 2024
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From May 2023 to May 2024